Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2021 | Twin Health | Series C | 155M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 11/2017 | Counsyl | Equity | 80M |
| 5/2017 | Outset Medical | Series C | 0 |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 5/2021 | Cue | Venture Round | 235M |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 3/2019 | Saama | Venture Round | 40M |
| 6/2016 | VitalConnect | Series B | 18M |
| 10/2020 | LianBio | Series A | 0 |
| 4/2019 | Kindbody | Series A | 15M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 1/2020 | Sonendo | Venture Round | 85M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 8/2020 | Freenome | Series C | 270M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 8/2018 | ReViral | Series B | 0 |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 12/2021 | Freenome | Series D | 300M |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 11/2021 | Sermonix | Series A | 40M |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 3/2022 | VivoSense | Series A | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 7/2019 | Kronos Bio | Series A | 105M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 12/2020 | Neuron23 | Series B | 80M |
| 7/2020 | Kindbody | Series B | 0 |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 5/2020 | Atea | Series D | 215M |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 7/2020 | Forge Biologics | Series A | 40M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 3/2022 | DNAnexus | Series H | 200M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 10/2014 | Invitae | Series F | 0 |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 7/2019 | Freenome | Series B | 160M |
| 4/2014 | Otonomy | Series D | 49M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 5/2017 | Vapotherm | Series D | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2020 | Metabolon | Venture Round | 72M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 1/2021 | IsoPlexis | Series D | 85M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 4/2021 | Renovia | Series C | 0 |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 3/2021 | Absci | Venture Round | 0 |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2020 | Genome Medical | Series B | 0 |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 5/2017 | Synlogic | Series C | 42M |
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 8/2020 | ReViral | Series C | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 4/2022 | Surf Bio | Seed | 16M |
| 11/2020 | Adagio Medical | Series E | 0 |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 9/2020 | Willow | Series C | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 9/2014 | Affimed | Debt Financing | 14M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 4/2021 | Forge Biologics | Series B | 120M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 10/2021 | Honor | Debt Financing | 300M |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 7/2018 | Alector | Series E | 133M |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 7/2014 | Virobay | Series B | 8M |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 5/2017 | Xontogeny | Series A | 15M |
| 5/2019 | ArcherDX | Series B | 60M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 9/2018 | Vapotherm | Series D | 0 |
| 4/2020 | Dynacure | Series C | 54.2M |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 1/2021 | Earli | Series A | 40M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
